Cormorant Asset Management

Activity in this selectionavidity-partners-2303dbde

By stage

Series C+3

Series B1

Biotech4

United States4

4 in this selection

Aug 10

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed

Jul 22

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Apr 15

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed